I-Mab Reports Dosing of TJ202/MOR202 in P-II Trial for Patients with Relapsed or Refractory Multiple Myeloma

 I-Mab Reports Dosing of TJ202/MOR202 in P-II Trial for Patients with Relapsed or Refractory Multiple Myeloma

I-Mab Reports Dosing of TJ202/MOR202 in P-II Trial for Patients with Relapsed or Refractory Multiple Myeloma

Shots:

  • The first P-II NCT03860038 trial involves assessing of TJ202/MOR202 as a 3L treatment in patients with R/R MM while the second P-II trial assess TJ202/MOR202 + lenalidomide (LEN) + dexamethasone (DEX) vs LEN + DEX in 1L R/R MM
  • In 2017, I-Mab in-licensed TJ202/MOR202 from MorphoSys while holds exclusive rights to develop and commercialize it in Mainland China, Hong Kong, Macao and Taiwan and is targeting the candidate in multiple myeloma and in certain autoimmune diseases, including systemic lupus erythematosus
  • TJ202/MOR202 is a mAb developed using MorphoSys’ HuCAL antibody technology used for targeting CD38 cells present on the surface of multiple myeloma cells

Click here to read full press release/ article | Ref: PRNewswire | Image: Behance

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post